

TRegRX - Restoring Immune Tolerance Through Regulatory T-Cell Innovation

TRegRx is a biotechnology company developing targeted therapies designed to restore regulatory T-cell function and re-establish immune tolerance in autoimmune, inflammatory, and allergic diseases.

The Science

Regulatory T cells, or Tregs, control inflammation and help prevent the immune system from attacking healthy tissue. TRegRx's platform is based on the discovery of a **correctable defect in interleukin-2 receptor signaling in Tregs from patients with autoimmune diseases**.

The company has developed **IL-2 fusion protein drug conjugates** designed to deliver therapeutic agents directly to Tregs and preserve the intracellular signaling proteins required for normal Treg function.

By correcting impaired IL-2 signaling, TRegRx aims to address an underlying mechanism of immune dysfunction—rather than treating only downstream symptoms or broadly suppressing the immune system.

Preclinical Validation

TRegRx has demonstrated preclinical proof of concept in models of:

- Systemic lupus erythematosus
- Multiple sclerosis
- Type 1 diabetes
- Allergic asthma

These findings support the potential development of a portfolio of therapies for diseases in which impaired immune tolerance plays a central role.

Foundational Intellectual Property

On July 7, 2026, the U.S. Patent and Trademark Office issued **U.S. Patent No. 12,673,109**, titled *"Compounds, Compositions, Methods, and Uses for Treating Cancer and Immunological Disorders."*

The patent strengthens TRegRx's proprietary position and supports continued development of its regulatory T-cell immune-restoration platform.

TRegRX - Restoring Immune Tolerance Through Regulatory T-Cell Innovation

Strategic Opportunity

TRegRx is seeking pharmaceutical and financial partners to advance:

- Lead-candidate selection and optimization
- Pharmacokinetic and pharmacodynamic studies
- IND-enabling development
- Process development and GMP manufacturing

The company is open to **investment, licensing, co-development, and strategic collaboration opportunities.**

Leadership

Michael Pavia, Ph.D. — Chief Executive Officer

Clarence R. Hurt, M.D. — Chief Scientist

Garry Fathman, M.D. — Co-Founder and Scientific Advisor

Luis Soares, Ph.D. — Co-Founder and Molecular Immunologist

Partnership, Investment, and Media Inquiries

Dr. Clarence R. Hurt

TRegRx, Inc.

crhurt@tregrx.com

tregrx.com